Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

26.21 +0.38 (+1.47%)
Official Closing Price Updated: 5:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
3 Steal-of-a-Deal Stocks to Snap Up Right Now
Here are three steal-of-a-deal stocks that offer meaningful upside for investors looking for stocks that are on sale now. 
Via InvestorPlace
Amgen's Upcoming Catalysts In 2024 Set To Unlock Multi-Billion Dollar Markets, Says Goldman Sachs
Amgen's growth outlook in 2024, with updates on key programs and upcoming catalysts. Goldman Sachs sees significant opportunities despite exclusivity losses. Dive into potential market moves and... 
Via Benzinga
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Better Bull Market Buy: Novavax vs. Pfizer
Bull markets usually favor stocks with promising growth prospects. 
Via The Motley Fool
Pfizer Unusual Options Activity For February 21
Via Benzinga
Exploring NYSE:PFE's dividend characteristics.
Exploring PFIZER INC (NYSE:PFE)'s dividend characteristics. 
Via Chartmill
7 Struggling Stocks to Sell Before Q2 2024
When you have stocks to sell, you also have an opportunity to reallocate that money into investments with a better growth window. 
Via InvestorPlace
Getting a Tax Refund? This Warren Buffett Stock Is a Great Way to Put It to Work
This Warren Buffett stock is a safe and proven capital appreciation vehicle. 
Via The Motley Fool
Novavax’s dispute resolution and upcoming earnings call
Novavax navigates legal settlements, earnings expectations, and competition, hoping their protein-based vaccines become a global health game-changer. 
Via MarketBeat
Topics Earnings
Exposures COVID-19 Financial
Recession-Proof Riches: 7 Stocks to Buy for Bulletproof Portfolio Growth
Explore recession-proof stocks thriving in Energy, Health Care, Industrials, and more, offering stability and growth amid economic turmoil. 
Via InvestorPlace
3 No-Brainer Stocks to Buy Right Now for Less than $50
You won't have to shell out much cash to invest in these great stocks. 
Via The Motley Fool
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
7 Stocks to Buy for Bargain Hunters on the Prowl
Wager on these top bargain stocks poised for a comeback, offering both long-term gains and income, away from the growth stock bubble. 
Via InvestorPlace
Why Range-Bound Moderna Could Get A Boost On Its Fourth-Quarter Report
The company unexpectedly came in with fourth-quarter earnings that beat projections. 
Via Investor's Business Daily
Moderna Stock Q4 Earnings Preview: RSV mRNA Vaccine Scrutiny, Diminishing Spikevax Revenue, FDA Approval In Focus
Moderna reports Q4 earnings on Feb. 22. Analysts expect $2.53B in revenue. Stock has faced challenges but potential for recovery with COVID-19 vaccine and FDA approval in 2024. 
Via Benzinga
Exposures COVID-19 Product Safety
These 3 Dividend Stocks Yield More Than 5% but Their Payout Ratios Are Over 100%. Are Dividend Cuts Coming?
Relying on payout ratio alone can sometimes give investors a misleading picture of just how safe a dividend payment is. 
Via The Motley Fool
3 Cheap Dividend Stocks to Snatch Up Now
Cheap dividend stocks offer rebound upside paired with an income source that is difficult to beat for most investors. 
Via InvestorPlace
Get Rich Quick with These 7 Growth Stocks to Buy Now
Here are seven growth stocks to buy that will let you know by their price action if the current bull market is ready to expand. 
Via InvestorPlace
Wall Street Favorites: 7 Long-Term Stocks With Strong Buy Ratings for February 2024
The stock market is soaring, and many analysts are worried about a bubble. Still, these seven long-term stocks are still great buys today. 
Via InvestorPlace
2 Ultra-High-Yield Dividend Stocks Billionaires Can't Stop Buying, and 1 They Can't Sell Fast Enough
Two brand-name income stocks with yields north of 6% were gobbled up by prominent billionaires in the December-ended quarter, while a dividend stock with a 15% yield found itself on the chopping... 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
7 Blue-Chip Stocks to Pick Up While They’re Down
Build a robust investment portfolio and make the most of the discount with these blue-chip stocks to buy and hold. 
Via InvestorPlace
ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures COVID-19 Financial Legal
ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX
WHY: NEW YORK, NY - (NewMediaWire) - February 18, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and... 
Via TheNewswire.com
Topics Lawsuit
Exposures COVID-19 Financial Legal
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
Patience will be rewarded with these stocks. 
Via The Motley Fool
MarketBeat Week in Review – 2/12 - 2/16
Higher inflation readings dampened expectations for rate cuts, and a shortened trading week may get more volatile when many retail stocks report earnings 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pfizer's Expansion Sparks Boom for these Healthcare REITs
Via Benzinga
7 F-Rated Stocks to Sell for February 2024
The stock market is off to a good start and there are plenty of great names out there. So don't hold on to your F-rated stocks to sell. 
Via InvestorPlace
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.